Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 9551 - 9575 of 10466 in total
Experimental
Experimental
Investigational
Tesaglitazar is a dual peroxisome proliferator-activated receptor alpha/gamma agonist which improves apolipoprotein levels in non-diabetic subjects with insulin resistance. Tesaglitazar is a proposed treatment for type 2 diabetes and has completed several phase III clinical trials, however in May 2006 AstraZeneca announced that they had discontinued further development.
Investigational
Investigational
PH-797804 has been investigated for the treatment of Osteoarthritis.
Investigational
Arbaclofen, or STX209, is the R-enantiomer of baclofen. It is believed to be a selective gamma-amino butyric acid type B receptor agonist, and has been investigated as a treatment for autism spectrum disorder and fragile X syndrome in randomized, double blind, placebo controlled trials. It has also been investigated as...
Investigational
UK-390,957 has been used in trials studying the treatment of Ejaculation.
Investigational
GSK2330672 has been investigated for the treatment of Diabetes Mellitus, Type 2.
Investigational
RRx-001 has been used in trials studying the treatment of Lymphomas, Brain Metastases, Cholangiocarcinoma, Colorectal Neoplasms, and Malignant Solid Tumor, among others.
Investigational
L-Baclofen has been used in trials studying the treatment of Trigeminal Neuralgia.
Investigational
Fosdagrocorat has been used in trials studying the treatment and basic science of Rheumatoid Arthritis.
Investigational
Displaying drugs 9551 - 9575 of 10466 in total